Morgan Stanley’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1
| Closed | -$2 | – | 7871 |
|
|
2022
Q4 | $2 | Sell |
1
-869
| -100% | -$1.53K | ﹤0.01% | 7868 |
|
|
2022
Q3 | $2K | Buy |
+870
| New | +$2.52K | ﹤0.01% | 7507 |
|
|
2022
Q2 | – | Sell |
-2
| Closed | – | – | 8089 |
|
|
2022
Q1 | $0 | Sell |
2
-1
| -33% | -$11 | ﹤0.01% | 8215 |
|
|
2021
Q4 | $0 | Sell |
3
-1,626
| -100% | -$29.2K | ﹤0.01% | 8190 |
|
|
2021
Q3 | $53K | Hold |
1,629
| – | – | ﹤0.01% | 6698 |
|
|
2021
Q2 | $70K | Sell |
1,629
-47
| -3% | -$1.93K | ﹤0.01% | 6514 |
|
|
2021
Q1 | $82K | Buy |
1,676
+984
| +142% | +$54K | ﹤0.01% | 6116 |
|
|
2020
Q4 | $25K | Buy |
692
+646
| +1,404% | +$20.3K | ﹤0.01% | 6371 |
|
|
2020
Q3 | $2K | Sell |
46
-1
| -2% | -$39 | ﹤0.01% | 6605 |
|
|
2020
Q2 | $2K | Hold |
47
| – | – | ﹤0.01% | 6475 |
|
|
2020
Q1 | $2K | Buy |
47
+15
| +47% | +$1.17K | ﹤0.01% | 6417 |
|
|
2019
Q4 | $2K | Sell |
32
-4
| -11% | -$463 | ﹤0.01% | 6520 |
|
|
2019
Q3 | $7K | Sell |
36
-14
| -28% | -$3.21K | ﹤0.01% | 6307 |
|
|
2019
Q2 | $13K | Buy |
50
+4
| +9% | +$1.34K | ﹤0.01% | 6063 |
|
|
2019
Q1 | $17K | Buy |
46
+42
| +1,050% | +$14.1K | ﹤0.01% | 6061 |
|
|
2018
Q4 | $1K | Hold |
4
| – | – | ﹤0.01% | 6538 |
|
|
2018
Q3 | $1K | Sell |
4
-1
| -20% | -$422 | ﹤0.01% | 6668 |
|
|
2018
Q2 | $2K | Sell |
5
-10
| -67% | -$4.71K | ﹤0.01% | 6566 |
|
|
2018
Q1 | $7K | Buy |
15
+7
| +88% | +$3.48K | ﹤0.01% | 6345 |
|
|
2017
Q4 | $4K | Buy |
8
+6
| +300% | +$3.95K | ﹤0.01% | 6370 |
|
|
2017
Q3 | $1K | Sell |
2
-1
| -33% | -$791 | ﹤0.01% | 6481 |
|
|
2017
Q2 | $3K | Buy |
+3
| New | +$2.19K | ﹤0.01% | 6426 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6633 |
|
|
2016
Q4 | – | Sell |
-2
| Closed | -$1K | – | 6584 |
|
|
2016
Q3 | $1K | Buy |
2
+1
| +100% | +$1.26K | ﹤0.01% | 6450 |
|
|
2016
Q2 | $1K | Hold |
1
| – | – | ﹤0.01% | 6457 |
|
|
2016
Q1 | $1K | Hold |
1
| – | – | ﹤0.01% | 6494 |
|
|
2015
Q4 | $1K | Sell |
1
-60
| -98% | -$78.3K | ﹤0.01% | 6586 |
|
|
2015
Q3 | $88K | Sell |
61
-25
| -29% | -$48.2K | ﹤0.01% | 5475 |
|
|
2015
Q2 | $191K | Buy |
86
+84
| +4,200% | +$263K | ﹤0.01% | 5269 |
|
|
2015
Q1 | $6K | Buy |
2
+1
| +100% | +$3.2K | ﹤0.01% | 6314 |
|
|
2014
Q4 | $4K | Hold |
1
| – | – | ﹤0.01% | 6373 |
|
|
2014
Q3 | $4K | Sell |
1
-53
| -98% | -$206K | ﹤0.01% | 6369 |
|
|
2014
Q2 | $210K | Buy |
54
+44
| +440% | +$166K | ﹤0.01% | 5129 |
|
|
2014
Q1 | $39K | Sell |
10
-55
| -85% | -$246K | ﹤0.01% | 5799 |
|
|
2013
Q4 | $240K | Buy |
65
+19
| +41% | +$72K | ﹤0.01% | 4936 |
|
|
2013
Q3 | $179K | Buy |
46
+21
| +84% | +$158K | ﹤0.01% | 4930 |
|
|
2013
Q2 | $242K | Buy |
+25
| New | +$277K | ﹤0.01% | 4728 |
|
Other funds holding FRTX
VF
CSS
TRCT
TSS
SCM
Morgan Stanley's FRTX Position: Q1 2023 in Review
Morgan Stanley sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q1 2023, closing a stake of 1 share — an estimated $2 sold.
Morgan Stanley first reported a position in FRTX in Q2 2013 and held it in 36 quarters. The position peaked at $242K in Q2 2013. 18 funds tracked by Wall St. Rank hold FRTX as of Q1 2023.
- Morgan Stanley reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Morgan Stanley sold 1 Fresh Tracks Therapeutics, Inc. Common Stock share in Q1 2023, an estimated $2.
- Morgan Stanley first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 36 quarters.
- Morgan Stanley's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $242K in Q2 2013.
- 18 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q1 2023.
Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.